摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-isopropoxy-pyridazine | 2792-90-7

中文名称
——
中文别名
——
英文名称
3-isopropoxy-pyridazine
英文别名
3-Isopropoxy-pyridazin;3-Propan-2-yloxypyridazine
3-isopropoxy-pyridazine化学式
CAS
2792-90-7
化学式
C7H10N2O
mdl
——
分子量
138.169
InChiKey
MSULMBMCHNWZRL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-isopropoxy-pyridazine羟基氨基磺酸potassium hydrogencarbonate 、 potassium iodide 作用下, 以 为溶剂, 生成
    参考文献:
    名称:
    Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors
    摘要:
    A novel series of pyrazolo[1,5-b]pyridazines have been synthesized and identified as cyclin dependant kinase inhibitors potentially useful for the treatment of solid tumors. Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta.
    DOI:
    10.1016/j.bmcl.2008.09.069
  • 作为产物:
    描述:
    3-氯-6-异丙氧基吡嗪 在 palladium on activated charcoal 、 乙醇 作用下, 生成 3-isopropoxy-pyridazine
    参考文献:
    名称:
    杂环研究中的化学研究。4. Mitteilung。哒嗪类衍生物
    摘要:
    描述了许多3-和6-位取代的哒嗪和4-甲基哒嗪用于药理研究。某些3,6-二烷氧基-哒嗪具有良好的抗惊厥性质。3,6-二肼基哒嗪在其药理特性上类似于降血压药“ A presoline”和“ Nepresol”。3-氨基-6-氯哒嗪的磺基衍生物具有优异的抗菌作用。
    DOI:
    10.1002/hlca.19540370115
点击查看最新优质反应信息

文献信息

  • [EN] PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR<br/>[FR] PIPÉRIDINE-AMIDES EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA GHRÉLINE
    申请人:PROSIDION LTD
    公开号:WO2011117254A1
    公开(公告)日:2011-09-29
    Compounds of formula (I) or pharmaceutically acceptable salts thereof, are useful for the treatment of diabetes and obesity.
    化合物的结构式(I)或其药学上可接受的盐,可用于治疗糖尿病和肥胖。
  • [EN] TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES
    申请人:GLOBAL BLOOD THERAPEUTICS INC
    公开号:WO2019036377A1
    公开(公告)日:2019-02-21
    The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    本公开提供了某些三环化合物,它们是组蛋白甲基转移酶G9a和/或GLP抑制剂,因此可用于治疗通过抑制G9a和/或GLP可治疗的疾病,如癌症和血红蛋白病(例如β地中海贫血和镰状细胞病)。还提供了含有这些化合物的药物组合物和制备这些化合物的方法。
  • Inhibitors of hepatitis C virus
    申请人:Gilead Pharmasset LLC
    公开号:US10335409B2
    公开(公告)日:2019-07-02
    Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    公开了式 I 的化合物 及其药学上可接受的盐类。还公开了使用所述化合物的方法和含有所述化合物的药物组合物。
  • Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer
    申请人:NAKAHARA Shinya
    公开号:US20080227937A1
    公开(公告)日:2008-09-18
    A process for producing an olefin copolymerization catalyst, comprising the step of contacting, with one another, (A) a solid catalyst component containing a titanium atom, a magnesium atom and a halogen atom, (B) an organoaluminum compound and/or organoaluminumoxy compound, and (C) a nitrogen-containing aromatic heterocyclic compound, whose one or more carbon atoms adjacent to its nitrogen atom are linked to an electron-donating group, or a group containing an electron-donating group; and a process for producing an olefin copolymer using the an olefin copolymerization catalyst.
  • INHIBITORS OF HEPATITIS C VIRUS
    申请人:Gilead Sciences, Inc.
    公开号:US20150175655A1
    公开(公告)日:2015-06-25
    Compounds of Formula I are disclosed, As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
查看更多